9 Meters Biopharma, Inc. (NMTR)
| Market Cap | 262.16M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -65.44M |
| Shares Out | 141.63M |
| EPS (ttm) | -0.97 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 5 |
| Last Price | $1.38 |
| Previous Close | $1.39 |
| Change ($) | -0.01 |
| Change (%) | -0.72% |
| Day's Open | 1.39 |
| Day's Range | 1.20 - 1.43 |
| Day's Volume | 8,462,043 |
| 52-Week Range | 0.37 - 2.26 |
RALEIGH, NC / ACCESSWIRE / March 1, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today the Company has appoi...
9 Meters Biopharma (NMTR) has moved higher as of late, but there could definitely be trouble on the horizon for this company.
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
NMTR stock is on the move Wednesday. Here's what you should know about 9 Meters Biopharma, which specializes in GI conditions.
Larazotide, a novel tight junction modulator, has shown positive effect in multiple lung models of acute respiratory distress, acute lung injury, and pulmonary fibrosis with potential effects ...
9 Meters Biopharma (NMTR) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Investors need to pay close attention to 9 Meters Biopharma (NMTR) stock based on the movements in the options market lately.
9 Meters Biopharma (NMTR) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Shares of 9 Meters Biopharma Inc (NASDAQ: NMTR) were ripping higher following a bullish initiation by Brookline Capital Markets.
NEW YORK, July 13, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiducia...
9 Meters Biopharma Inc. (NASDAQ: NMTR) may not be a household name right now, but one brokerage firm sees huge potential upside.
About NMTR
9 Meters Biopharma, a clinical-stage biotechnology company, focuses on patients with rare disorders and unmet needs. The company's pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease. It is developing NM-002, a long-acting injectable GLP-1 agonist that is in a Phase 2 clinical trial for SBS; and Larazotide, a Phase 3-stage therapeutic in development for celiac disease. The company also develops NM-003, a proprietary long-acting GLP-2 agonist; and NM-004, a double-cleaved mesalamine with an immunomodulator for dev... [Read more...]
| Industry Biotechnology | Founded 2012 |
| CEO Sandeep Laumas | Employees 8 |
| Stock Exchange NASDAQ | Ticker Symbol NMTR |